Advertisement
New Zealand markets open in 4 hours 30 minutes
  • NZX 50

    11,803.28
    -49.52 (-0.42%)
     
  • NZD/USD

    0.5944
    +0.0024 (+0.40%)
     
  • ALL ORDS

    7,937.90
    +35.90 (+0.45%)
     
  • OIL

    83.08
    +1.18 (+1.44%)
     
  • GOLD

    2,342.30
    -4.10 (-0.17%)
     

6,214 Orion Corporation A shares converted into B shares

Orion Oyj
Orion Oyj

ORION CORPORATION
STOCK EXCHANGE RELEASE - OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
28 JUNE 2022 at 9.30 EEST

6,214 Orion Corporation A shares converted into B shares

In accordance with Section 3 of the Articles of Association of Orion Corporation, 6,214 A shares have been converted into 6,214 B shares. The conversion has been entered into the Trade Register on 28 June 2022.

The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 34,476,321 A shares and 106,657,957 B shares. The number of votes of the company's shares is after the conversion 796,184,377.

ADVERTISEMENT

Orion Corporation

Jari Karlson

CFO

   

Olli Huotari

SVP, Corporate Functions

 


Contact person:
Tuukka Hirvonen, Investor Relations, tel. +358 10 426 2721

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are oncology and pain. Orion's net sales in 2021 amounted to EUR 1,041 million and the company had about 3,350 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.